Valion Bio, Inc. (VBIO)

Valion Bio, Inc., formerly Tivic Health Systems, is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways to protect tissues and modulate immune responses. The company changed its name and ticker from Tivic Health and TIVC to Valion Bio and VBIO in 2026 after transforming from a consumer medical device business into a drug developer.

Its lead asset is entolimod, a Toll-like receptor 5 agonist designed to protect bone marrow and gastrointestinal tissue. It is being developed as a medical countermeasure for acute radiation syndrome under the FDA's Animal Rule pathway, with potential use by U.S. government stockpiles, and is also being explored for chemotherapy-induced neutropenia. The company is also developing a next-generation TLR5 agonist.

Valion Bio is headquartered in San Antonio, Texas, and owns a contract development and manufacturing business that supports production of its product candidates and serves outside clients.